Medical Center Pharmacy, Inc., Cleveland, TN

Is Medical Center Pharmacy, Inc. registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility, with FDA’s note “De-registered as an Outsourcing Facility”.

Does Medical Center Pharmacy, Inc. hold a Tennessee pharmacy license?

State pharmacy license records for Tennessee are not checked: the Department of Health’s license verification site did not respond to this index’s requests. This index reads only that state’s board actions. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054017608 for MEDICAL CENTER PHARMACY, CLEVELAND, TN, status NOT RENEWED, as of Nov 13, 2026.

Has Medical Center Pharmacy, Inc. had a state board action or FDA letter?

FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 1 Form 483 (Apr 9, 2020) for Medical Center Pharmacy, Inc. State board actions: no Tennessee Board of Pharmacy action under this exact name and city was found in the Board of Pharmacy sections of the Tennessee Department of Health’s monthly Disciplinary Action Reports (actions dated January 2004 to April 2026) on Nov 15, 2026.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Medical Center Pharmacy, Inc.
Location
Cleveland, TN
Type as FDA labels it
503A
FDA’s note
De-registered as an Outsourcing Facility
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Apr 9, 2020
FDA Data Dashboard inspections
2 inspections: 2 OAI; 2 published Form 483s
Form 483 text on this page
1 Form 483, 11 observations
State board records
Not checked (license records); board actions matched: 0

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Medical Center Pharmacy, Inc., a 503A facility, with 1 dated action.

Document
Apr 9, 2020Form 483483 Issued 04/09/2020FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Medical Center Pharmacy, Inc., Cleveland, TN (FEI number 3010536120), matched to this page by exact name, city and state. It lists 2 inspections: 2 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Apr 9, 2020Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30105361201123219
Oct 13, 2015Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3010536120945314

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 11 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Apr 9, 2020: 11 observations

Firm on the cover
Medical Center Pharmacy, Inc, 24 01 N. Ocoee Street, Cleveland, TN 37311-3853
FEI number
3010536120
Establishment type on the cover
Producer of Sterile and Non-Sterile Drug Products
FDA district office on the cover
U.S. FOOD AND DRUG ADMINISTRATION 404 BNA DRIVE BLDG 200 SUITE 400 NASHVILLE, TN 37217
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Sources of non-microbial contamination were observed in the JSO 5 classified aseptic processing areas that are difficult to clean, particle-generating and visibly dirty.

Specifically, on 03/09/2020, we observed the following inside your firm's Laminar Air Flow Hood LAFH) (lS0-5 classified, <Redacted B4>, where aseptic human and veterinarian drug operations take place, including but are not limited to, intrathecal sterile drug products:

A. Visible discoloration what appears to be brown residue (approximately 3-inches in height) was observed on the HEPA screen of your firm's <Redacted B4> LAFH;

B. Visible discoloration that appears to be residue buildup was observed on the inside comers of the HEP A screen;

C. What appeared to be chipped paint was observed on the inside corner of the LAFH;

D. Gaps were observed on the inside of your firm's transparent acrylic plastic side wall of the LAFH where the workbench meets the wall;

E. Caulking was observed on the inside of your firm's LAFH where the workbench meets the HEPA screen. The caulking is not smooth and not easily cleanable;

F. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Disinfecting agents and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile.

THI S IS A RE PE AT OB SERVATION

Specifically,

A. Your firm uses a non-sterile bactericidal <Redacted B4> or <Redacted B4> cleaning solution, non-sterile <Redacted B4> wipes, and non-sterile <Redacted B4> wipes during routine <Redacted B4> cleanings of your classified areas where aseptic operations are performed, for example, but not limited to, the interior surfaces of IS0-5 equipment:

L Laminar Air Flow Hood (LAFH) (IS0-5 classified <Redacted B4>, located in your firm's Buffer Room;

Your firm does not render these products sterile prior to use. According to your firm's aseptic processing lead pharmacy technician who conducts <Redacted B4> cleaning of your firm's aseptic processing areas, these non-sterile products are also used in the Buffer Room (ISO 7 classified) and anteroom (ISO 8 classified).

According to your firm's prescription log, dated April 2019 -March 2020, your firm produces, but are not limited to the following routes of administration in your LAFH (ISO 5 classified): ...

Read the full 483 (PDF on fda.gov)

Observation 3

You did not make adequate product evaluation and take remedial action where microbial contamination iwas found to be present in the lSO 5 classified aseptic processing or areas surrounding the ISO 5 classified iarea.

Specifically,

A. According to your firm's Certification Report, dated 16 April 2019, a viable air sample (VAS) revealed:

l. In the <Redacted B4> hood <Redacted B4>, taken at the center, approximately 6" from the rear:

[(D)

1. Bacterial Results and Trending: Nineteen (19) CFUs were identified as Bacillus; Coag-Neg. Staphylococcus; Micrococcus.

2. In the Anteroom (ISO-7 classified) on the "counter near center of room":

1. Fungal Results and Trending: Three (3) CFUs identified as Exophiala; and

ii. Bacterial Results and Trending: Seventeen (17) CFUs identified as Coag-Neg. Staphylococcus; Micrococcus.

According to your firm 's Sterile Log, the following products were produced on 16 April 2019, including but are not limited to:

Drug Name

Lot Number

Vitamin B Comolex High Potency lniection

04162019@4

Nandrolone Decanoate 200mg/1ml 04162019@8 Anastrozole/Testosterone Cypionate Oil Injection lmg/200mg/mL

04162019@9 Estradiol Valerate/Testosterone Cypionate 40mg/50mg Per mL ...

Read the full 483 (PDF on fda.gov)

Observation 4

Your aseptic processing conditions do not offer sufficient assurance that the finished product will meet an endotoxin specification appropriate for its route of administration.

Specifically, according to your firm's pharmacistt-in-charge, your firm doesn't perform any bacterial endotoxin testing for your finished intrathecal drug products. These preparations are made using non-sterile active pharmaceutical ingredients (APis). No bacterial endotoxin testing was performed on these APTs prior to use in aseptic operations. Furthermore, your firm does not calculate the bacterial endotoxin limit. According to your firm's written procedure, 9.140: "Bacterial Endotoxin (Pyrogen) Testing", lendotoxin testing is to be performed at least every <Redacted B4> and for <Redacted B4>

In addition, the expiration dates of your intrathecals are inconsistent, for example, but not limited to:

Date Compounded

Drug Name

Lot Number

Expiration Date on Rx Label

Days until expiry

D

Fentanyl/Morphine/Bupivacaine/Hydromorphone Intrathecal 2500mcg/25mg/7.5mg/l 0mg

02172020@18

~ I year

Clonidine/Baclofen 200mcg/2000mcg

02202020(@7

~1 year

Baclofen (Preservative Free) 3000mcg/mL

02192020@12

1 day ...

Read the full 483 (PDF on fda.gov)

Observation 5

Your aseptic processing conditions do not offer sufficient assurance that the finished product is sterile.

Specifically, the air pressure gauge used to perform <Redacted B4> of all <Redacted B4> have not been calibrated since 2015.

Observation 6

Media fills are not conducted to simulate aseptic production operations that represent the most-challenging and stressful conditions

Specifically, on 03/16/2020, your pharmacist-in-charge stated the largest batch size produced at your firm under aseptic operations is <Redacted B4>. However, the media fill (aseptic processing simulation) records performed by your firm's personnel, who engage in aseptic operations, only represent 25% of your firm's largest batch size.

In addition, your pharmacist-in-charge stated the most-challenging aseptic operation performed at your facility is for inhalation nebulizers. However, the media fills performed are for <Redacted B4> products.

Observation 7

You had inadequate HEPA filter coverage and airflow over the area to which sterile product was exposed.

Specifically,

A. TSO 5 Classified Areas:

I. LAFH: A loose light fixture with exposed wiring was observed on the ceiling of your firm's LAFH.

B. ISO 7 Classified Areas:

l. HEPA filters were not sealed around each perimeter of the support frame:

i. HEPA filter frames: Missing caulk was observed around the perimeter of the HEPA filter frames that seal the HEPA filters to the ceiling, located in your firm's buffer room (JSO-7 classified):

I. Located directly above your firm's LAFH (lSO-5 classified);

2. Located approximately 6 feet from your firm's LAFH (fSO-5 classified); and

3. Located approximately 10 feet from your firm' s LAFH (1SO-5 classified).

action with the FDA represenlative(s) during the inspection or submit this infom)ation to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above,

2. Light fixture: Missing caulk was observed around your firm's light fixture

3. Ceiling: A crack observed in the sheetrock located on your firm' ceiling directly above the ISO 5 hood.

C. ISO 8 Classified Areas:

I. ...

Read the full 483 (PDF on fda.gov)

Observation 8

Equipment and Materials or supplies were not disinfected prior to entering the aseptic processing areas.

Specifically,

A. On 03/16/2020, your pharmacist in charge admitted the glassware (e.g. beakers), containing drug products used in aseptic operations are uncovered and are not disinfected or sanitized when placed in your firm's unclassifie (b) (4) •. This'( D) ( 4) !anteroom (ISO 8 classified) to your firm's buffer room (ISO 7 classified). According to your firm's PIC, this same beaker remains uncovered in the (b) <4> (located in the anteroom - TSO 8 classified),[(5) (4) I 4 '{bH > (unclassified), staging tray (located in the buffer room - ISO 7 classified), and in the LAFH

(1S0 5 classified). B. Your lead pharmacy technician, who conducts cleaning on a routine basis, admitted the trash bins are removed from the buffer room (ISO 7 classified) and placed into the anteroom (ISO 8 classified) when the floors are cleaned. However, the trash bins are not disinfected or sanitized when entering an area of higher classification.

Observation 9

fhe area adjacent to the ISO 5 classified aseptic processing areas had difficult to clean, particle-generating and visibly dirty equipment or surface.

A. Buffer Room (ISO-7 classified) Area:

I. On 03/09/2020, what appeared to be signs of rust and chipped paint was observed on your firm's LAFH (ISO-5 classified) support frame, located approximately I-inch from where aseptic operations are performed.

2. On 03/09/2020, what appeared to be visible signs of dust build-up was observed on your firm's LAFH (1SO-5 classified) support frame, located approximately 1-inch from where aseptic operations are performed.

THIS IS A REPEAT OBSERVATION On 03/09/2020, a chair was observed to not be suitable as a cleanroom chair. What appeared to be signs of rust was observed on the back support and legs of the chair, and what appeared to be paint chippings were observed on the upper back portion of the chair.

4. On 03/09/2020, what appeared to be signs of rust was observed on the storage rack where cleaning supplies and drug components are stored.

1. ...

Read the full 483 (PDF on fda.gov)

Observation 10

You produced hazardous drugs without providing adequate containment, segregation, cleaning of work surfaces, cleaning of utensils and cleaning of personnel to prevent cross-contamination. Specifically, your firm produces hazardous and non-hazardous, sterile and non-sterile, drug products without adequate segregation. On 03/09/2020, we observed what appears to be white powder residue in your firm 's[(D) (4) ood [(~)]4)]According to your finn's lead pharmacy technician, who iengages in aseptic operations on a routine basis, the status of the (b) <4) is clean. All[(b) (4) 'drugs (hazardous and non-hazardous) are[b) (4) J in this non-dedicated (b) (4) Your ftnn does not nave a i.separate processing sched~l~ when producing hazardous drug products from non-hazardous drug7 ucts. r-'or example, but are not hm1ted to, on 1/23/2020, your firm used fluorouracil API [(l:5) (~) (b) (4) ] a hazardous drug product, to produce a non-sterile cream. However, your firm also engagedin im;ept1c operations before and after this fluorouracil lot was produced.

Furthermore, your firm does not have appropriate cleaning solutions or appropriate controls in place after handling hazardous drug products.

Observation 11

Parameters for sterilization are not lethal to resistant microorganisms.

Specifically, your firm uses <Redacted B4> using the <Redacted B4> using <Redacted B4> for depyrogenation of glassware used in the production of sterile drug products. Your firm has not performed an endotoxin challenge for the glassware <Redacted B4>

Linked 483s whose text is not shown

State board of pharmacy records

State pharmacy license records for Tennessee are not checked: the Department of Health’s license verification site did not respond to this index’s requests. This index reads only that state’s board actions. Board actions source.

What this covers: Board of Pharmacy actions against pharmacies and other business licensees from the Department of Health’s monthly Disciplinary Action Reports (260 of 263 monthly reports read, 137 with a Board of Pharmacy section). The reports list final board actions for the month named, worded as the department gives them; each action is dated by its report month. Actions against individual pharmacists and technicians are not copied. An entry that gives a city but no state is read as a Tennessee address, as the reports write them. Tennessee pharmacy licenses are not checked. Actions in the data are dated January 2004 to April 2026.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054017608LICENSED PHARMACYMEDICAL CENTER PHARMACYCLEVELAND, TNNOT RENEWED

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.